Codexis, Inc., a leading enzyme engineering company, announced that management will participate in three upcoming virtual investment conferences.
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences.
- The UBS Global Healthcare Virtual Conference – May 24, 2021 at 11:00 a.m. ET, corporate presentation; a live webcast of the conference presentation will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. Replays of the webcast will be archived for 30 days following the event.
- The SynBioBeta Synthetic Biology Biopharma Conference – May 26, 2021 at 11:10 a.m. ET, Exponential Change: What Should We Expect for Biopharma 2025 Panel
- The Benchmark Company Healthcare House Call Conference – May 26, 2021, management will attend and host 1x1 investor meetings
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Codexis’ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Codexis undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Codexis’ business in general, please refer to Codexis’ prospectus supplement to be filed with the SEC, including the documents incorporated by reference therein, which include Codexis’ Annual Report on Form 10-K filed with the SEC on March 1, 2021, Codexis’ Quarterly Report on Form 10-Q filed with thee SEC on May 7, 2021, and Codexis’ other periodic reports filed with the SEC.
Investor Relations Contact:
Argot Partners
Stephanie Marks/Carrie McKim
(212) 600-1902
Codexis@argotpartners.com
